Cargando…

Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods

BACKGROUND: Youth with serious mental illness may experience improved psychiatric stability with second generation antipsychotic (SGA) medication treatment, but unfortunately may also experience unhealthy weight gain adverse events. Research on weight loss strategies for youth who require ongoing an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reeves, Gloria M, Keeton, Courtney, Correll, Christoph U, Johnson, Jacqueline L, Hamer, Robert M, Sikich, Linmarie, Hazzard, Lindsey, Alderman, Cheryl, Scheer, Abigail, Mabe, Micah, Kapoor, Sandeep, Sheridan, Eva, Borner, Irmgard, Bussell, Kristin, Pirmohamed, Sara, Bethea, Terrence C, Chekuri, Raja, Gottfried, Rhoda, Reinblatt, Shauna P, Santana, Erin, Riddle, Mark A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846140/ https://www.ncbi.nlm.nih.gov/pubmed/23947389 http://dx.doi.org/10.1186/1753-2000-7-31

Ejemplares similares

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Challenges in the diagnosis and treatment of depression in autism spectrum disorders across the lifespan
por: Chandrasekhar, Tara, et al.
Publicado: (2015)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
por: Maloney, Ann E, et al.
Publicado: (2010)

A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials
por: Coates, Margaret, et al.
Publicado: (2018)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
por: Carbon, Maren, et al.
Publicado: (2014)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Successful live birth after transfer of blastocyst and frozen blastocyst from rescue ICSI with application of polarized light microscopy for spindle examination on unfertilized eggs
por: Moon, Jeong Hee, et al.
Publicado: (2015)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
por: Bak, Maarten, et al.
Publicado: (2021)

Healthy-Weight Kindergarten Children with Autism Spectrum Disorder May Become Overweight and Obese during the First Few Years of Elementary School
por: Eliasziw, Misha, et al.
Publicado: (2021)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

When Adverse Childhood Experiences Present to a Statewide Child Psychiatry Access Program
por: Ferro, Rebecca A., et al.
Publicado: (2023)

Mortality risk of antipsychotic augmentation for adult depression
por: Gerhard, Tobias, et al.
Publicado: (2020)

O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT
por: Rubio, Jose, et al.
Publicado: (2018)

Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics
por: Skonieczna-Żydecka, Karolina, et al.
Publicado: (2020)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents
por: Frank, Bettina, et al.
Publicado: (2023)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial
por: Hollander, Eric, et al.
Publicado: (2022)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
por: Hieronymus, Fredrik, et al.
Publicado: (2021)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS
por: Rubio, Jose, et al.
Publicado: (2018)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation
por: Findling, Robert L, et al.
Publicado: (2008)

Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis
por: Kishimoto, Taishiro, et al.
Publicado: (2023)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
por: Correll, Christoph U., et al.
Publicado: (2022)

Recent Advances in Understanding and Mitigating Adipogenic and Metabolic Effects of Antipsychotic Drugs
por: Gohlke, Julia M., et al.
Publicado: (2012)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
por: Potkin, Steven G., et al.
Publicado: (2020)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
por: Litman, Robert, et al.
Publicado: (2023)

Use of antipsychotics in Denmark 1997–2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses
por: Højlund, M., et al.
Publicado: (2021)

Manual para planificar la administración de emergencias
por: Sikich, Geary W.
Publicado: (1978)

Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials
por: Pagsberg, A K, et al.
Publicado: (2014)

Atypical antipsychotics, more than just an antipsychotic
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4anfpogur1g4228hr4g8aca746